Outsourcing is best option for those who lacks the expertise or who lacks resources and this is the case with smaller companies. But now a days major pharma company is also outsourcing there clinical trial to CRO’s because it’s found that CRO’s are able to finish this trials faster and now company can use its remaining resources to focus on other task like CAPA for findings, risk mitigation, regulatory or marketing.

Her is some finding which I tried to discuss over here.
According to the 2016 Nice Insight Contract Research – Preclinical and Clinical Survey,2 there was a big jump in expenditure for outsourcing services this year, maintaining the continuously escalating spend over the last five years. The majority of companies (38%) now spend $51 million to $100 million for outsourcing, and another 18% spend more than $100 million. That is a big increase from the previous year’s Nice Insight survey, where the vast majority (64%) spent $10 million to $50 million on outsourcing and only 23% spent more than $50 million.

Rising costs and falling productivity, among other trends, are driving industry companies to outsource an increasing range of functions to CROs to achieve cost savings. In addition to providing substantial global capacity to drug developers, CROs have become a critical contributor to clinical trial programs. According to a recent report by ResearchandMarkets, clinical trials conducted by CROs are completed up to 30% more quickly than those conducted in-house by pharma companies.3 That, of course, translates into a considerable cost savings and likely a faster market launch.